NCT02550249已完成2 期
Phase II Study of Neoadjuvant Nivolumab in Patients With Glioblastoma Multiforme
Clinica Universidad de Navarra, Universidad de Navarra1 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2015年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 29
- 试验地点
- 1
- 主要终点
- Changes in percentage and level of expression of Programmed Death-Ligand 1 (PD-L1) by tumor cells and lymphocytes, assessed at baseline and following neoadjuvant nivolumab in Glioblastoma multiforme (GBM).
研究概览
简要总结
Neoadjuvant nivolumab will be administered to patients with primary and recurrent glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery.
详细描述
Neoadjuvant nivolumab will be administered to patients with primary and recurrent glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery until toxicity or progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent.
- •Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing and other requirements of the study.
- •Patients with GBM that are candidates to primary or salvage resection surgery, according to the following criteria:
- •Patients may have received previous treatments for GBM. There is no limit on previous treatment lines, as long as the other inclusion criteria are met.
- •Patients in whom surgery can be safely delayed for a minimum period of 2 weeks following the administration of the first dose of nivolumab, in the opinion of the investigator.
- •Eastern Cancer Oncology Group (ECOG) performance status of 0-
- •Patients with ECOG>1 due to neurological symptoms considered to be reversible following surgery, according to investigator´s criteria will be eligible
- •Life expectancy >12 weeks.
- •Adequate organ function defined by:
- •Bone Marrow Reserve: white blood cells (WBC): ≥2000/ mm3 absolute neutrophil count (ANC) ≥1500x 109/L; platelet count ≥100000/ mm3 100 x 109/L; hemoglobin ≥9.0 g/dL).
- •Hepatic: bilirubin <1.5 times the upper limit of normality (ULN), AST and ALT <3.0 × ULN (BR< 3 x ULN for patients with Gilbert´s Syndrome).
- •Renal: creatinine < 1.5 x ULN or estimated creatinine clearance > 40 ml/min, using the Cockcroft-Gault formula.
排除标准
- •Presence of extracranial disease.
- •Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive the planned therapy (including brain surgery), or interfere with the interpretation of study results.
- •Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- •Previous treatment with a PD-1, PDL1 or CTLA-4 targeted therapy
- •Treatment with any anti-cancer drug or radiation therapy within the last 14 days. A shorter interval can be approved by the principal investigator, if deemed appropriate.
- •Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents), with the exception of control of cerebral edema, or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- •Pregnant or breastfeeding patients.
- •Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). Routine testing is not required.
- •Positive tests for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV RNA) indicating active or chronic infection.
- •History of allergy to study drug components or of severe hypersensitivity reactions to any monoclonal antibodies.
- •Prisoners or subjects who are involuntarily incarcerated or who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.
- •Subjects unable (due to existent medical condition, e.g, pacemaker or implantable cardioverter defibrillator device) or unwilling to have a head contrast enhanced MRI and/or a CT scan of the brain.
- •Concomitant or prior malignancy that, in the opinion of the investigator contraindicates GBM surgery or can interfere with the results of the study, in the opinion of the investigator.
- •Known drug or alcohol abuse.
研究组 & 干预措施
Nivolumab
Experimental
Nivolumab 3 mg every 2 weeks
干预措施: Nivolumab (Drug)
结局指标
主要结局
Changes in percentage and level of expression of Programmed Death-Ligand 1 (PD-L1) by tumor cells and lymphocytes, assessed at baseline and following neoadjuvant nivolumab in Glioblastoma multiforme (GBM).
时间窗: 1 neoadjuvant cycle followed by surgery (4 weeks). Evaluation will be performed at baseline and after the neoadjuvant cycle
We will assess levels of expression of Programmed Death-Ligand 1 (PD-L1) by tumor cells and lymphocytes at baseline and following neoadjuvant nivolumab in Glioblastoma multiforme (GBM). The specific outcome will be the changes in these levels.
次要结局
- Efficacy: response rate assessed by Response Assessment in Neuro-Oncology (RANO) criteria(1 neoadjuvant cycle followed by surgery (4 weeks))
- Safety: toxicity assessed by Common Toxicity Criteria (CTC) version 4(1 neoadjuvant cycle followed by surgery (4 weeks))
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator PhenotypeGliomaGlioblastomaNCT03718767National Cancer Institute (NCI)62
招募中
2 期
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable MelanomaMelanomaNCT06365619University of Utah25
已完成
2 期
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal CancerNasopharyngeal Nonkeratinizing CarcinomaRecurrent Nasopharynx CarcinomaStage III Nasopharyngeal Carcinoma AJCC v7Stage IV Nasopharyngeal Carcinoma AJCC v7Stage IVA Nasopharyngeal Carcinoma AJCC v7Stage IVB Nasopharyngeal Carcinoma AJCC v7Stage IVC Nasopharyngeal Carcinoma AJCC v7NCT02339558National Cancer Institute (NCI)45
终止
2 期
Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a MelanomaMelanomaNCT03259425University of Utah7
终止
2 期
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory MyelomaRelapsed Multiple MyelomaRefractory Multiple MyelomaNCT04119336Andrew Yee, MD2